logoThe People's Perspective on Medicine

Should We Worry About the New Holds on Vaccine Trials?

Holds on vaccine trials are not unexpected, but they could delay development of an effective protection against COVID-19.
Should We Worry About the New Holds on Vaccine Trials?
Doctor giving patient vaccine, flu shot. Doctor making a vaccination in the shoulder of patient

People all around the world are waiting impatiently for vaccines or monoclonal antibody treatments that might help control the pandemic. This week brought bad news on several fronts. Two different companies put new holds on vaccine trials. Moreover, a pharmaceutical firm developing monoclonal antibodies has also stopped its study for the time being.

Why Are There New Holds on Vaccine Trials?

Johnson & Johnson is one of the key vaccine developers. This week it put a hold on its Phase 3 trial due to an unexplained illness in one of the volunteers. The company is trying to determine whether this is an adverse reaction to the vaccine. Perhaps this participant became ill from causes unrelated to the vaccine itself. On the other hand, if the shot was the cause, scientists need to know about it. 

This delay follows on the heels of a pause for a different vaccine. Astra Zeneca resumed its testing in the UK, South Africa, Brazil, India and Japan. But the FDA has not yet finished its investigation and allowed testing to restart in the US. Late in September, still another company, Inovio, had its planned late-stage vaccine trial pushed off indefinitely. Both the manufacturers and the FDA have emphasized that such holds on vaccine trials are an expected part of the process.

Clinical Trial Delay for Monoclonal Antibodies from Eli Lilly:

In addition, Eli Lilly has announced a temporary halt to its clinical trial of monoclonal antibodies used to neutralize SARS-CoV-2. The Data Safety Monitoring Board detected a safety problem. However, the company has not yet identified the nature of the problem.

Lilly is also in trouble with the FDA for quality control problems in its New Jersey plant. While those troubles predate the pandemic, they could definitely affect the outcome, as Lilly plans to make this anti-COVID drug in that facility. 

With new holds on vaccine trials from multiple manufacturers, we hope that other promising vaccine candidates are performing well in their studies. Ideally, several companies will establish the safety and efficacy of their COVID-19 vaccines by next spring.

Rate this article
4.2- 31 ratings
About the Author
Terry Graedon, PhD, is a medical anthropologist and co-host of The People’s Pharmacy radio show, co-author of The People’s Pharmacy syndicated newspaper columns and numerous books, and co-founder of The People’s Pharmacy website. Terry taught in the Duke University School of Nursing and was an adjunct assistant professor in the Department of Anthropology. She is a Fellow of the Society of Applied Anthropology. Terry is one of the country's leading authorities on the science behind folk remedies. .
Join over 150,000 Subscribers at The People's Pharmacy

We're empowering you to make wise decisions about your own health, by providing you with essential health information about both medical and alternative treatment options.